natalizumab
Sign in to saveAlso known as AN100226m, PB006, anti-alpha4 integrin, anti-VLA4, antegran, natalizumab-sztn
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458283255
- Drug.type
- mab
- Drug.image
- Natalizumab 4IRZ.png
- Drug.caption
- Natalizumab Fab fragment bound to the headpiece of an α4-integrin. From PDB .
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- alpha-4 integrin
- Drug.tradename
- Tysabri, others
- Drug.MedlinePlus
- a605006
- Drug.DailyMedID
- Natalizumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG03
- Drug.biosimilars
- natalizumab-sztn, Tyruko
- Drug.legal_AU
- S4
via Wikipedia infobox
Research
3,689 papers- Natalizumab.Drugs of today (Barcelona, Spain : 1998) · 2006
- PB006: A Natalizumab Biosimilar.Clinical drug investigation · 2024
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.The New England journal of medicine · 2006
- Natalizumab update.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2007
- Natalizumab-induced pneumonitis.Journal of neurology · 2022
via PubMed
Wikidata facts
- Subclass of
- protein
- Has use
- medication
Show 8 more facts
- route of administration
- intravenous infusion and defusion
- World Health Organisation international non-proprietary name
- natalizumab
- defined daily dose
- 10
- subject has role
- monoclonal antibody
- medical condition treated
- Crohn's disease
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
- side effect
- nausea
via Wikidata · CC0
~14 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- Multiple sclerosis
- Crohn's disease
- Interactions
- History
- Society and culture
- Legal status
- Biosimilars
- References
- Further reading
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.
Natalizumab is a monoclonal antibody which targets a protein called α4β1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage.
Excerpted from Wikipedia’s “natalizumab” article, available under the CC BY-SA 4.0 licence.